brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride
DIMETANE-DX (brompheniramine maleate; dextromethorphan hydrobromide; pseudoephedrine hydrochloride) is clinical pharmacology brompheniramine maleate is a histamine antagonist, specifically an h 1 -receptor-blocking agent belonging to the alkylamine class of antihistamines. Approved for nasal congestion due to the common cold, hay fever, other upper respiratory allergies temporarily relieves these symptoms due to hay fever (allergic rhinitis) runny nose itchy and 2 more indications. First approved in 1984.
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
DIMETANE-DX is a fixed-dose combination oral syrup containing brompheniramine maleate (H1-receptor antagonist), dextromethorphan hydrobromide (antitussive), and pseudoephedrine hydrochloride (nasal decongestant). It treats upper respiratory allergy and cold symptoms including nasal congestion, runny nose, sneezing, cough, and watery eyes. The triple mechanism addresses allergic response suppression, cough suppression, and nasal vasoconstriction simultaneously.
As LOE approaches, the brand team is likely in transition mode with focus shifting from growth maintenance to pipeline continuity and managed decline strategies.
CLINICAL PHARMACOLOGY Brompheniramine maleate is a histamine antagonist, specifically an H 1 -receptor-blocking agent belonging to the alkylamine class of antihistamines. Antihistamines appear to compete with histamine for receptor sites on effector cells. Brompheniramine also has anticholinergic…
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
DIMETANE-DX offers limited career growth opportunity as a LOE-approaching mature brand in a saturated OTC market. Roles are defensive, focused on managed decline, generic transition planning, and operational efficiency rather than innovation or expansion.